Amherst Advises on Sale of Acute Care Pharmaceuticals

Amherst Advises on Sale of Acute Care Pharmaceuticals

Amherst Partners, LLC (“Amherst”) is pleased to announce the sale of Acute Care Pharmaceuticals (“Acute Care” or “the Company”) to The Tranzonic Companies (“Tranzonic”), a portfolio company of PNC Riverarch Capital. Amherst acted as the exclusive financial advisor to Acute Care in connection with the transaction.

About Acute Care Pharmaceuticals

Acute Care Pharmaceuticals, headquartered in San Diego, California, is a market-leading supplier of branded USP 792 and USP 800 compliant disposable cleanroom supplies and apparel used in the manufacturing, compounding, and handling of hazardous and non-hazardous drugs.

Cleanroom disposable products include dry wipers, pre-saturated wipers, alcohol & disinfectants, tacky mats & refills, testing kits, intravenous seals, apparel, gloves and glove liners, chemo mats, and chemo neutralizers. The Company also has a specialty wholesale pharmaceutical and related medical supplies operation that assembles, distributes, and restocks cardiac, anaphylactic, and trauma (“CAT”) kits used in emergency situations by hospitals, doctor clinics, and dental offices.

The Company’s products are sold through major pharmaceutical wholesalers AmerisourceBergen, Cardinal, and McKesson, as well as IDN groups. Acute Care also maintains contracts with 13 key GPO’s that cover 5,000+ acute care hospitals in the United States.

About the Transaction

Consistent with their estate planning objectives, the Company’s founders Tom and Jan McGowan engaged Amherst to conduct a sale process and transition their ownership of Acute Care. Amherst managed a comprehensive buyer identification process, ultimately engaging a range of prospective buyers capable of scaling the attractive platform represented by the Company. Tranzonic, a Cleveland, Ohio-based manufacturer of disposable products serving the industrial sector emerged as a preferred buyer for Acute Care based, in part, on the opportunity to expand a synergistic product line and enter the rapidly growing healthcare sector. Tom McGowan will maintain an active role in the business from an advisory capacity.